RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
NCT06468267
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG:
Thiotepa
Sponsor
Xianmin Song, MD